Skip to content
value.today

Ollin Biosciences, Inc.

🇺🇸 Austin, Texas, USABiotechnologyFounded 2022
Total raised
$156 M
1 round on record
Latest round
$156 M
May 2026
First round on record
May 2026
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ollin Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2026$156 MNo. 1$50 to $250 million

Ollin Biosciences, Inc.: Raise no. 1, May 2026

Investors in this round

32 investors had bought by the notice of Jun 24, 2026: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$156 M of $330 M offered; $174 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Ehrlich · Executive Officer, Director
  • Alaa Halawa · Director
  • Cariad Chester · Director
  • Fred Cohen · Director
  • Jason Coloma · Director
  • Paul Berns · Director
  • Travis Murdoch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jason Ehrlich, Chief Executive Officer. Newest notice filed Jun 24, 2026. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ollin Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ollin Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ollin Biosciences, Inc.
NameRoleNamed in
Jason EhrlichExecutive officerJun 2026
Alaa HalawaDirectorJun 2026
Cariad ChesterDirectorJun 2026
Fred CohenDirectorJun 2026
Jason ColomaDirectorJun 2026
Jason EhrlichDirectorJun 2026
Paul BernsDirectorJun 2026
Travis MurdochDirectorJun 2026